Overview
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
Status:
Completed
Completed
Trial end date:
2007-02-01
2007-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the long-term sustained clearance rate of superficial basal cell carcinoma during a 5 year period following treatment with imiquimodPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
MEDA Pharma GmbH & Co. KGTreatments:
Imiquimod
Criteria
Inclusion Criteria:- Have one superficial BCC - primary tumour
- Minimum tumour area of 0.5cm2, maximum diameter of 2.0cm.
- If female and of child bearing potential, negative pregnancy test and willing to use
medically acceptable method of contraception.
Exclusion Criteria:
- Evidence of clinically significant, unstable medical conditions.
- Evidence of Gorlin syndrome, metastatic tumour or tumour with high probability of
metastatic spread, have or have had within last 5 years other malignant cancers of the
skin at target tumour site.
- Have received defined treatments in tumour site or surrounding area.
- Any dermatological disease in the target tumour site or surrounding area.
- Have had a systemic bacterial or viral infection within 2 weeks prior to study
initiation.